Implications of metabolic dysfunction associated fatty liver disease in COVID-19

doi:10.12998/wjcc.v11.i6.1275

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 6

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3097)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

193

WORD

HTML

1829

Figures (1-2)

454

Sum=2520

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

153

Download

364

Sum=517

Feb 26, 2023 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Feb 26, 2023; 11(6): 1275-1286
Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1275

Full Size Figure Download Figure

Figure 1 Order of risk of drug-induced liver injury. ALT: Alanine transaminase; AST: aspartate transaminase; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; MAFLD: Metabolic associated fatty liver disorder.

Citation: Chakraborty R, Sharma D, Kapoor DU, Dwivedi A, Khabiya R, Sen S. Implications of metabolic dysfunction associated fatty liver disease in COVID-19. World J Clin Cases 2023; 11(6): 1275-1286
URL: https://www.wjgnet.com/2307-8960/full/v11/i6/1275.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i6.1275